by Elena Iemma | Jan 26, 2021 | Events, Webinars
The FDA hosted a virtual workshop January 26, 2021 to provide updates and foster discussions around non-clinical assays for comparative immunogenicity risk assessment of generic peptide products. EpiVax CEO/CSO, Annie De Groot, presented an update on EpiVax’s...
by Adam | Dec 29, 2020 | News
PROVIDENCE, R.I., Dec. 29, 2020 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) today provides an update on the advancement of the company’s peptide therapeutic immunogenicity assessment program. The PANDA (Peptide Abbreviated New Drug...
by Annie De Groot | Sep 23, 2020 | Events, Webinars
Catch the replay We’re sorry, but this live event has passed. You may watch the replay here. The video is hosted by Dropbox, in which case you will need to either be logged in to an account, or downlow the video in order to view the full recording. Should you...
by Annie De Groot | Aug 20, 2020 | Events, News
With the 2020 TIDES USA Virtual conference right around the corner, we at EpiVax are proud to sponsor this event, as we have year after year. Our CEO and leader in #FearlessScience Dr. Anne De Groot will be presenting a talk on a generic case study New Dogs/Old...
by Adam | Oct 5, 2018 | News
This original article was published on October 2nd, 2018 in ConvergenceRI. PROVIDENCE, RI – The U.S. Food and Drug Administration announced on Tuesday, Oct. 2, that the federal agency has awarded EpiVax and CUBRC a $1 million contract over two years to establish best...
